Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 446 shares of the firm’s stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $23.78, for a total value of $10,605.88. Following the completion of the sale, the chief financial officer now directly owns 1,117 shares in the company, valued at $26,562.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

  • On Friday, September 14th, Michael Burkes Brophy sold 108,108 shares of Natera stock. The stock was sold at an average price of $24.31, for a total value of $2,628,105.48.
  • On Monday, July 2nd, Michael Burkes Brophy sold 26,870 shares of Natera stock. The stock was sold at an average price of $18.29, for a total value of $491,452.30.

NASDAQ NTRA opened at $24.78 on Thursday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -10.33 and a beta of 2.21. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of -3.32. Natera Inc has a fifty-two week low of $8.60 and a fifty-two week high of $29.62.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, August 8th. The medical research company reported ($0.55) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.55). Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The company had revenue of $63.07 million for the quarter, compared to the consensus estimate of $61.71 million. During the same quarter in the previous year, the business earned ($0.55) earnings per share. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. equities analysts anticipate that Natera Inc will post -2.05 EPS for the current year.

A number of large investors have recently bought and sold shares of the business. Northern Trust Corp raised its position in Natera by 1.5% in the first quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock valued at $3,483,000 after purchasing an additional 5,428 shares during the period. Swiss National Bank raised its position in Natera by 13.2% in the first quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock valued at $444,000 after purchasing an additional 5,600 shares during the period. State of Wisconsin Investment Board raised its position in Natera by 30.4% in the second quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 7,000 shares during the period. Trexquant Investment LP raised its position in Natera by 76.6% in the second quarter. Trexquant Investment LP now owns 22,643 shares of the medical research company’s stock valued at $426,000 after purchasing an additional 9,820 shares during the period. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Natera in the second quarter valued at $200,000. Institutional investors own 66.31% of the company’s stock.

A number of brokerages have recently issued reports on NTRA. BidaskClub lowered Natera from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Zacks Investment Research lowered Natera from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th. TheStreet raised Natera from a “d” rating to a “c-” rating in a research note on Thursday, August 9th. Canaccord Genuity boosted their price objective on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 16th. Finally, Craig Hallum boosted their price objective on Natera from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $23.14.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Outstanding Shares

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.